rna helicase-a

YK 4-279, an inhibitor of RNA Helicase A (RHA), binds to the oncogenic transciption factor EWS-FLI1.

CMLD012073 is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. It inhibits NIH/3T3 cells (IC50: 10 nM). CMLD012073 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A).

Supinoxin (RX-5902) is an orally active inhibitor of phosphorylated-p68 RNA helicase and a potent first-in-class anti-cancer agent, inducing cell apoptosis and inhibiting the growth of TNBC cancer cell lines (IC50s: 10 nM - 20 nM).

GBM CSCs-IN-1 (Compound (−)-20), a rocaglate derivative, potently inhibits glioblastoma stem cells (GBM CSCs) and exhibits an EC50 of 45 nM by targeting the RNA helicase DDX3. Additionally, it induces apoptosis in these cells.

SARS-CoV-2 nsp13-IN-7 (Compound 6r) is an inhibitor of SARS-CoV-2 nsp13, with an IC50 of 0.28 μM. This compound disrupts the helicase function of nsp13 by binding to its 5' RNA site and ATP binding site, and it serves as a lead compound for developing antiviral drugs targeting SARS-CoV-2 nsp13.

Fli-1-IN-1 (compound 21) fumarate is an FLI1-targeting agent that binds directly to and inhibits the interaction of the EWS-FLI1 protein. Since EWS-FLI1 interacts with RNA helicase A, Fli-1-IN-1 fumarate's inhibition of EWS-FLI1 suggests potential anticancer properties.

Brr2-IN-3 (Brr2 Inhibitor C9) is an allosteric inhibitor of the spliceosomal RNA helicase Brr2. Brr2 is implicated in autosomal-dominant retinitis pigmentosa (a group of progressive retinal degenerative disorders).

Avenanthramide A is a naturally occurring, orally active plant defensin that binds to and inhibits RNA helicase DDX3, induces mitochondrial swelling and CRC cell apoptosis, increases ROS production, exhibits antitumor activity, and can be used in colorectal cancer research.

RK33 (RK 33) is a first-in-class small molecule inhibitor of DDX3 (a RNA helicase) and causes G1 cell cycle arrest, induces apoptosis, and promotes radiation sensitization in DDX3-overexpressing cells.

DHX9-IN-2 is an inhibitor targeting ATP-dependent RNA de-helicase A (DHX9) with anticancer and antitumor activity for cancer research.

DHX9-IN-1 is a potent ATP-dependent RNA helicase A (DHX9) inhibitor, exhibiting an IC50 of 9.45 nM and demonstrating antitumor activity [1].

DHX9-IN-13 (389) serves as an inhibitor of the RNA helicase DHX9, demonstrating a cellular target engagement EC50 of 3.4 μM. It is primarily utilized in cancer research [1].

DHX9-IN-17 (186) serves as an inhibitor of the RNA helicase DHX9, demonstrating a target engagement EC50 value of 0.161 μM in cellular assays. It is utilized in cancer research [1].

DHX9-IN-3 (Compound 621) acts as an ATP-dependent inhibitor of RNA helicase A (DHX9), and holds potential for use in cancer research [1].

DHX9-IN-6 is a highly effective ATP-dependent RNA helicase A (DHX9) inhibitor, used in cancer research.

DHX9-IN-7 (550) acts as an inhibitor of the RNA helicase DHX9, displaying a potent EC 50 value of 0.105 μM for cellular target engagement. It is frequently utilized in cancer research [1].

Fli-1-IN-1 (compound 21) serves as a FLI1 inhibitor by binding directly to the EWS-FLI1 protein, disrupting its interaction with RNA helicase A. This inhibition holds potential anticancer properties [1].